

Simon De Denus

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/193460/simon-de-denus-publications-by-year.pdf>

Version: 2023-05-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

37
papers

691
citations

13
h-index

26
g-index

42
ext. papers

846
ext. citations

4.7
avg, IF

3.38
L-index

#	Paper	IF	Citations
37	Leveraging large observational studies to discover genetic determinants of drug concentrations: A proof-of-concept study.. <i>Clinical and Translational Science</i> , 2022 ,	4.8	1
36	Population Pharmacokinetics of Candesartan in Patients with Chronic Heart Failure. <i>Clinical and Translational Science</i> , 2021 , 14, 194-203	4.8	0
35	Isocyanate derivatization coupled with phospholipid removal microelution-solid phase extraction for the simultaneous quantification of (S)-metoprolol and (S)-hydroxymetoprolol in human plasma with LC-MS/MS. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2021 , 204, 114263	3.4	1
34	Comparative effectiveness and safety of high-dose rivaroxaban and apixaban for atrial fibrillation: A propensity score-matched cohort study. <i>Pharmacotherapy</i> , 2021 , 41, 379-393	5.6	0
33	Pharmacogenomics of the Efficacy and Safety of Colchicine in COLCOT. <i>Circulation Genomic and Precision Medicine</i> , 2021 , 14, e003183	4.9	2
32	Comparative Effectiveness and Safety of Low-Dose Oral Anticoagulants in Patients With Atrial Fibrillation.. <i>Frontiers in Pharmacology</i> , 2021 , 12, 812018	5.4	0
31	Oral Anticoagulant Prescription Trends, Profile Use, and Determinants of Adherence in Patients with Atrial Fibrillation. <i>Pharmacotherapy</i> , 2020 , 40, 40-54	5.6	40
30	Opinion, experience and educational preferences concerning pharmacogenomics: an exploratory study of Quebec pharmacists. <i>Pharmacogenomics</i> , 2020 , 21, 235-245	2.5	4
29	CYP2D6 polymorphism and its impact on the clinical response to metoprolol: A systematic review and meta-analysis. <i>British Journal of Clinical Pharmacology</i> , 2020 , 86, 1015-1033	3.7	9
28	A genetic model of ivabradine recapitulates results from randomized clinical trials 2020 , 15, e0236193		
27	A genetic model of ivabradine recapitulates results from randomized clinical trials 2020 , 15, e0236193		
26	A genetic model of ivabradine recapitulates results from randomized clinical trials 2020 , 15, e0236193		
25	A genetic model of ivabradine recapitulates results from randomized clinical trials 2020 , 15, e0236193		
24	Is there a potential association between spironolactone and the risk of new-onset diabetes in a cohort of older patients with heart failure?. <i>European Journal of Clinical Pharmacology</i> , 2019 , 75, 837-847 ^{2.6}		4
23	Rationale, design, and preliminary results of the Quebec Warfarin Cohort Study. <i>Clinical Cardiology</i> , 2018 , 41, 576-585	3.2	9
22	Subclinical Inflammation in Heart Failure: A Neutrophil Perspective. <i>Canadian Journal of Cardiology</i> , 2018 , 34, 717-725	2	10
21	Cardiopulmonary, biomarkers, and vascular responses to acute hypoxia following cardiac transplantation. <i>Clinical Transplantation</i> , 2018 , 32, e13352	3.7	

20	A comparison of the effects of selective and non-selective mineralocorticoid antagonism on glucose homeostasis of heart failure patients with glucose intolerance or type II diabetes: A randomized controlled double-blind trial. <i>American Heart Journal</i> , 2018 , 204, 190-195	4.7	5
19	Drug Shortages: Patients and Health Care Providers Are All Drawing the Short Straw. <i>Canadian Journal of Cardiology</i> , 2017 , 33, 283-286	2	23
18	Older adults with heart failure treated with carvedilol, bisoprolol, or metoprolol tartrate: risk of mortality. <i>Pharmacoepidemiology and Drug Safety</i> , 2017 , 26, 81-90	2.6	3
17	Diagnosis, Prevalence, Awareness, Treatment, Prevention, and Control of Hypertension in Cameroon: Protocol for a Systematic Review and Meta-Analysis of Clinic-Based and Community-Based Studies. <i>JMIR Research Protocols</i> , 2017 , 6, e102	1.9	4
16	Pharmacogenomics of heart failure: a systematic review. <i>Pharmacogenomics</i> , 2016 , 17, 1817-1858	2.5	7
15	Platelet-Related Variants Identified by Exomechip Meta-analysis in 157,293 Individuals. <i>American Journal of Human Genetics</i> , 2016 , 99, 40-55	10.5	60
14	Large-Scale Exome-wide Association Analysis Identifies Loci for White Blood Cell Traits and Pleiotropy with Immune-Mediated Diseases. <i>American Journal of Human Genetics</i> , 2016 , 99, 22-39	10.5	41
13	Exome Genotyping Identifies Pleiotropic Variants Associated with Red Blood Cell Traits. <i>American Journal of Human Genetics</i> , 2016 , 99, 8-21	10.5	48
12	Genetic markers associated with cutaneous adverse drug reactions to allopurinol: a systematic review. <i>Pharmacogenomics</i> , 2015 , 16, 755-67	2.5	16
11	Risk Factors for Chronic Renal Insufficiency Following Cardiac Transplantation. <i>Annals of Transplantation</i> , 2015 , 20, 576-87	1.3	13
10	Changes in cardiopulmonary reserve and peripheral arterial function concomitantly with subclinical inflammation and oxidative stress in patients with heart failure with preserved ejection fraction. <i>International Journal of Vascular Medicine</i> , 2014 , 2014, 917271	1.2	13
9	Rare and low-frequency coding variants in CXCR2 and other genes are associated with hematological traits. <i>Nature Genetics</i> , 2014 , 46, 629-34	35.2	92
8	Pharmacogenomics and heart failure in congenital heart disease. <i>Canadian Journal of Cardiology</i> , 2013 , 29, 779-85	2	1
7	Association between renal function and CYP3A5 genotype in heart transplant recipients treated with calcineurin inhibitors. <i>Journal of Heart and Lung Transplantation</i> , 2011 , 30, 326-31	1	18
6	Temporal variations in hematocrit values in patients with left ventricular dysfunction: Relationship with cause-specific mortality and morbidity and optimal monitoring--further insights from SOLVD. <i>Canadian Journal of Cardiology</i> , 2008 , 24, 45-8	2	5
5	Effects of AGTR1 A1166C gene polymorphism in patients with heart failure treated with candesartan. <i>Annals of Pharmacotherapy</i> , 2008 , 42, 925-32	2.8	27
4	Temporal increases in subclinical levels of inflammation are associated with adverse clinical outcomes in patients with left ventricular dysfunction. <i>Journal of Cardiac Failure</i> , 2006 , 12, 353-9	1	11
3	Quantification of the risk and predictors of hyperkalemia in patients with left ventricular dysfunction: a retrospective analysis of the Studies of Left Ventricular Dysfunction (SOLVD) trials. <i>American Heart Journal</i> , 2006 , 152, 705-12	4.7	53

- 2 Rate vs rhythm control in patients with atrial fibrillation: a meta-analysis. *Archives of Internal Medicine*, **2005**, 165, 258-62 168
- 1 Key articles and guidelines in the management of hypertension. *Pharmacotherapy*, **2004**, 24, 1385-99 5.6 8